KPRX
Kiora Pharmaceuticals, Inc.
There isn't enough reported data to score KPRX yet.
KPRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
KPRX's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
KPRX PE Valuation
KPRX has no meaningful PE right now: it lost money over the past year.
KPRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect KPRX's losses to shrink, with revenue holding steady.
KPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.79 | -$0.53 |
| Q2 2026 | -$2.50 | +$0.58 |
| Q1 2026 | -$2.70 | +$0.37 |
| Q4 2025 | -$2.64 | -403% |
| Q3 2022 | -$367.47 | +$183.33 |
| Q2 2022 | -$417.60 | +$187.20 |
| Q1 2022 | -$478.80 | +$136.80 |
| Q4 2021 | -$514.80 | +$122.40 |
KPRX lost $2.79 per share over the past year, a bigger loss than the year before.
KPRX Quarterly Revenue
KPRX's revenue is growing: $1M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -169% | N/A |
| Q2 2024 | -12724% | N/A |
| Q1 2024 | 83% | N/A |
KPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$557.9K | +$715.6K |
| Q1 2026 | -$3.2M | -$462.2K |
| Q4 2025 | -$2.3M | -$51.3K |
| Q3 2025 | -$1.3M | -238% |
| Q1 2025 | -$2.7M | -120% |
| Q4 2024 | -$2.2M | +$374K |
| Q3 2024 | $920.1K | +$3.4M |
| Q1 2024 | $13.6M | +$16.7M |
KPRX has burned cash in almost every quarter: −$8M over the past year, against −$5M the year before.
KPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +117K shares |
| 1 year | +44% | +1.9M shares |
| 3 years | +2940% | +6.1M shares |
| 5 years | +49822% | +6.3M shares |
KPRX has 6M diluted shares, up 44% from a year ago.
KPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -0.8x | Net Cash |
| Q3 2024 | -1.1x | Net Cash |
| Q2 2024 | -2.5x | Net Cash |
| Q1 2024 | -12.0x | Net Cash |
KPRX has more cash than debt.
KPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.6 | Oversold |
| Stochastic | 1.2 | Oversold |
KPRX's weekly RSI is 23 (oversold) and its Stochastic is 1 (oversold).
KPRX PE vs Healthcare Sector
KPRX has no meaningful PE right now: it lost money over the past year.
KPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.09 | 36% below |
| 20 week MA | $2.40 | 45% below |
| 50 week MA | $2.31 | 42% below |
| 100 week MA | $2.64 | 50% below |
| 200 week MA | $6.48 | 79% below |
KPRX is in a downtrend: it's below all five of its weekly moving averages, and 79% below its 200-week average.
KPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3,351.6 | $2,138.4 | -36% |
| 2021 | $2,138.4 | $312.5 | -85% |
| 2022 | $312.5 | $22.1 | -93% |
| 2023 | $22.1 | $4.70 | -79% |
| 2024 | $4.70 | $3.29 | -30% |
| 2025 | $3.29 | $1.97 | -40% |
| 2026 YTD | $1.97 | $1.33 | -32% |
KPRX has finished every year since 2020 lower, and it's down 32% so far in 2026.